Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 64

Results For "2022"

1455 News Found

Modi to dedicate three National Ayush Institutes to the nation on Dec 11
Policy | December 08, 2022

Modi to dedicate three National Ayush Institutes to the nation on Dec 11

These satellite institutes will further strengthen the research, international collaborations and facilitate affordable Ayush services for the larger community.


Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati
Policy | December 08, 2022

Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati

More women centric initiatives being the need of the hour for holistic development


TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma
News | December 07, 2022

TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma

TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022


Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData
News | December 07, 2022

Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData

The use of procalcitonin testing for sepsis management is highest in the US


Concord Biotech gets SEBI nod for IPO
News | December 07, 2022

Concord Biotech gets SEBI nod for IPO

The IPO is a complete OFS by existing shareholder Helix Investment Holdings


Briefs: Natco Pharma & Lupin
News | December 06, 2022

Briefs: Natco Pharma & Lupin

Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.


Biocon Biologics elevates Shreehas Tambe as MD & CEO
People | December 06, 2022

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.


Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
News | December 05, 2022

Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers